Soluble CD4 molecules neutralize human immunodeficiency virus type 1 - PubMed (original) (raw)

. 1988 Jan 7;331(6151):84-6.

doi: 10.1038/331084a0.

Affiliations

• PMID: 2829024
• DOI: 10.1038/331084a0

Soluble CD4 molecules neutralize human immunodeficiency virus type 1

A Traunecker et al. Nature. 1988.

Abstract

Human immunodeficiency virus (HIV) infection can bring about total collapse of the immune system by infecting helper T lymphocytes which express CD4, the molecule which mediates interaction between the cell surface and viral envelope glycoprotein gp120 (refs 3-10). HIV apparently escapes the effects of neutralizing antibodies in vivo by generating new variants which must still interact with CD4 to maintain a cycle of infection. One route to block HIV infection, therefore, could use solubilized CD4 protein to inhibit attachment of the virus to its target cell. We have used recombinant DNA techniques to generate soluble forms of CD4, and show here that these are potent inhibitors of HIV infection in vitro.

PubMed Disclaimer

Similar articles

• HIV infection is blocked in vitro by recombinant soluble CD4.
  Fisher RA, Bertonis JM, Meier W, Johnson VA, Costopoulos DS, Liu T, Tizard R, Walker BD, Hirsch MS, Schooley RT, et al. Fisher RA, et al. Nature. 1988 Jan 7;331(6151):76-8. doi: 10.1038/331076a0. Nature. 1988. PMID: 2829022
• A soluble CD4 protein selectively inhibits HIV replication and syncytium formation.
  Hussey RE, Richardson NE, Kowalski M, Brown NR, Chang HC, Siliciano RF, Dorfman T, Walker B, Sodroski J, Reinherz EL. Hussey RE, et al. Nature. 1988 Jan 7;331(6151):78-81. doi: 10.1038/331078a0. Nature. 1988. PMID: 2829023
• A soluble form of CD4 (T4) protein inhibits AIDS virus infection.
  Deen KC, McDougal JS, Inacker R, Folena-Wasserman G, Arthos J, Rosenberg J, Maddon PJ, Axel R, Sweet RW. Deen KC, et al. Nature. 1988 Jan 7;331(6151):82-4. doi: 10.1038/331082a0. Nature. 1988. PMID: 3257544
• Characterization of CD4 glycoprotein determinant-HIV envelope protein interactions: perspectives for analog and vaccine development.
  Farrar WL, Harel-Bellan A, Ferris DK. Farrar WL, et al. Crit Rev Immunol. 1988;8(4):315-39. Crit Rev Immunol. 1988. PMID: 2850890 Review.
• [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
  Azevedo-Pereira JM, Santos-Costa Q. Azevedo-Pereira JM, et al. Acta Med Port. 2008 Sep-Oct;21(5):497-504. Epub 2009 Jan 16. Acta Med Port. 2008. PMID: 19187693 Review. Portuguese.

Cited by

• Extracellular domain, hinge, and transmembrane determinants affecting surface CD4 expression of a novel anti-HIV chimeric antigen receptor (CAR) construct.
  Zenere G, Wu C, Midkiff CC, Johnson NM, Grice CP, Wimley WC, Kaur A, Braun SE. Zenere G, et al. PLoS One. 2024 Aug 12;19(8):e0293990. doi: 10.1371/journal.pone.0293990. eCollection 2024. PLoS One. 2024. PMID: 39133676 Free PMC article.
• Extracellular domain, hinge, and transmembrane determinants affecting surface CD4 expression of a novel anti-HIV chimeric antigen receptor (CAR) construct.
  Zenere G, Wu C, Midkiff CC, Johnson NM, Grice CP, Wimley WC, Kaur A, Braun SE. Zenere G, et al. bioRxiv [Preprint]. 2023 Oct 26:2023.10.25.563930. doi: 10.1101/2023.10.25.563930. bioRxiv. 2023. PMID: 37961145 Free PMC article. Updated. Preprint.
• Fusion Proteins CLD and CLDmut Demonstrate Potent and Broad Neutralizing Activity against HIV-1.
  Fu M, Xiao Y, Du T, Hu H, Ni F, Hu K, Hu Q. Fu M, et al. Viruses. 2022 Jun 23;14(7):1365. doi: 10.3390/v14071365. Viruses. 2022. PMID: 35891347 Free PMC article.
• Enhancement of CD4 Binding, Host Cell Entry, and Sensitivity to CD4bs Antibody Inhibition Conferred by a Natural but Rare Polymorphism in the HIV-1 Envelope.
  Ratcliff AN, Venner CM, Olabode AS, Knapp J, Pankrac J, Derecichei I, Gibson RM, Finzi A, Li Y, Mann JFS, Arts EJ. Ratcliff AN, et al. J Virol. 2022 Jul 27;96(14):e0185121. doi: 10.1128/jvi.01851-21. Epub 2022 Jul 5. J Virol. 2022. PMID: 35862673 Free PMC article.
• Rational Design of A Novel Small-Molecule HIV-1 Inactivator Targeting Both gp120 and gp41 of HIV-1.
  Pu J, Dai Y, Wang Q, Lu L, Zhang J, Xu W, Xie L, Wang S, Yu F, He X, Jiang S. Pu J, et al. Front Pharmacol. 2021 Jan 25;11:613361. doi: 10.3389/fphar.2020.613361. eCollection 2020. Front Pharmacol. 2021. PMID: 33569006 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program